Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial
Authors' conclusion
Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy.
Study context
- Population
- Patients with rheumatic diseases, osteoporosis drug-naive, newly treated with prednisolone ≥ 15 mg/day69.2% women
- Participants
- 39 patients
- Comparison
- Romosozumab (ROMO) for 12 months followed by denosumab (DMAb) for 24 months vs DMAb or bisphosphonates (BP) alone for 36 months
- Primary endpoint
- Median percent change in lumbar spine BMD from baseline
- Follow-up
- Up to 36 months
Primary result
As reported in the abstract
Lumbar spine BMD, median percent change from baseline
ROMO-DMAb
11.3
median · IQR 6.8–13.8 · %
DMAb
9.4
median · IQR 4.7–13.5 · %
BP
2.1
median · IQR −1.3–6.8 · %
Further findings
Femoral neck and total hip bone mineral density (BMD) change
- Similar between ROMO-DMAb and DMAb; increases much smaller than in the lumbar spine
Serum total P1NP and TRACP-5b · from month 3
- Decreased in all groups
Original publication
Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial. Osteoporos Int. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →